<sentence id="0">Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells .</sentence>
<sentence id="1">Janus kinase 3 ( JAK3 ) is a cytoplasmic tyrosine kinase required for T cell development and activated by cytokines that utilize the interleukin-2 ( IL-2 ) receptor common gamma chain ( gamma(c) ) .</sentence>
<sentence id="2">Genetic inactivation of JAK3 is manifested as severe combined immunodeficiency disease ( SCID ) in humans and mice .</sentence>
<sentence id="3">These findings have <scope type="spec" id="0"> <cue type="spec" id="0">suggested</cue> that JAK3 represents a pharmacological target to control certain lymphoid-derived diseases</scope> .</sentence>
<sentence id="4">Here we provide novel evidence that AG-490 potently inhibits the autokinase activity of JAK3 and tyrosine phosphorylation and DNA binding of signal transducer and activator of transcription 5a and 5b ( STAT5a/b ) .</sentence>
<sentence id="5">Similar inhibitory effects were observed with other cytokines that use gamma(c) .</sentence>
<sentence id="6">AG-490 also inhibited IL-2-mediated proliferative growth in human T cells with an IC50 ) = 25 microM that was partially recoverable .</sentence>
<sentence id="7">Moreover , we demonstrate that this inhibitor prevented tetanus toxoid antigen-specific T cell proliferation and expansion but failed to block activation of Zap70 or p56Lck after anti-CD3 stimulation of human T cells .</sentence>
<sentence id="8">Taken together , these findings <scope type="spec" id="2"> <cue type="spec" id="2">suggest</cue> that AG-490 inhibits the JAK3-mediated Type II signaling pathway but <scope type="neg" id="1"><cue type="neg" id="1">not</cue> the T cell receptor-derived Type I pathway</scope> and possesses therapeutic potential for T cell-derived pathologies such as graft-versus-host disease , allergy , and autoimmune disorders</scope> .</sentence>